Please assess the completion status of the following clinical trial:

Trial Title: Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* men and non-pregnant, non-breastfeeding women~* anticipated to be severely immobilized for at least 24 hours after randomization~* hospitalized with one of the following~  * congestive heart failure~ * acute respiratory failure,~ * acute infection without septic shock,~ * acute rheumatic disorders~ * acute ischemic stroke with lower extremity hemiparesis or hemi paralysis~Exclusion Criteria:~* a condition requiring prolonged anticoagulation or anti-platelets~* active bleeding or at high risk of bleeding~* contraindication to anticoagulant therapy~* general conditions in which subjects are not suitable to participate in the study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Betrixaban (Type: EXPERIMENTAL): Daily oral (PO) betrixaban capsules for 35 to 42 days and subcutaneous (SQ) injections of enoxaparin placebo for 10 ± 4 days
- Enoxaparin (Type: ACTIVE_COMPARATOR): Daily subcutaneous (SQ) injections of enoxaparin for 10 ± 4 days and oral (PO) betrixaban placebo capsules for 35 to 42 days

Based on this trial design, predict the completion outcome and termination type (if applicable).